Gardasil Anal Cancer Indication: CBER Has No Concerns, But What Will ACIP Think?

A Center for Biologics Evaluation and Research clinical reviewer sees no problem with using an anal dysplasia endpoint, or extrapolating male data to females, to support approval of Merck’s human papillomavirus vaccine Gardasil for prevention of anal cancer.